Journal Mobile Options
Table of Contents
Vol. 18, No. 4, 2001
Issue release date: February 2002
Section title: Review
Exp Clin Immunogenet 2001;18:176–198
(DOI:10.1159/000049197)

Incorporation of Long CDR3s into V Domains: Implications for the Structural Evolution of the Antibody-Combining Site

Ramsland P.A. · Kaushik A. · Marchalonis J.J. · Edmundson A.B.
aCrystallography Program, Oklahoma Medical Research Foundation, OklahomaCity, Okla., USA; bDepartment of Pathobiology, University of Guelph,Ont., Canada; cDepartment of Microbiology and Immunology, College of Medicine, University of Arizona, Tucson,Ariz., USA; dStructural Biology Laboratory, The Austin Research Institute, Heidelberg, Vic., Australia

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Review

Published online: 3/4/2002
Issue release date: February 2002

Number of Print Pages: 23
Number of Figures: 9
Number of Tables: 2

ISSN: 0254-9670 (Print)
eISSN: 1421-9948 (Online)

For additional information: http://www.karger.com/ECI

Abstract

Available data suggest that ‘primitive’ antibody-combining sites often include longer than average HCDR3s. Long HCDR3 sequences have been reported in diverse vertebrates, including humans, cattle, camels and sharks. These long HCDR3 segments contain unusual sequence features such as stretches of Gly or Pro residues and multiple Cys residues. We examined how longer than average HCDR3s were accommodated in the V domains of human, murine and camel antibodies with known three-dimensional structures. The main conclusions were that (1) HCDR3s longer than 12 residues should protrude outward from the V domains; (2) descending HCDR3 polypeptides may utilize VL (including LCDR3) constituents as a platform, supporting the protruding segments; (3) intra- and inter-HCDR disulfides are frequently formed to rigidify the structure of HCDR3 or the combining site, and (4) V and C domains were possibly more similar in primordial antibodies than they are in their present day counterparts.


  

Author Contacts

Allen B. Edmundson, PhD
Crystallography Program, Oklahoma Medical Research Foundation
825 NE 13th Street, Oklahoma City, OK 73104 (USA)
Tel. +1 405 271 1673, Fax +1 405 271 7953
E-Mail Allen-Edmundson@omrf.ouhsc.edu

  

Article Information

Received: Received: June 21, 2001
Number of Print Pages : 23
Number of Figures : 9, Number of Tables : 2, Number of References : 100

  

Publication Details

Experimental and Clinical Immunogenetics

Vol. 18, No. 4, Year 2001 (Cover Date: Released Feburary 2002)

Journal Editor: K. Bauer, Heidelberg
ISSN: 0254–9670 (print), 1421–9948 (Online)

For additional information: http://www.karger.com/journals/eci


Article / Publication Details

First-Page Preview
Abstract of Review

Published online: 3/4/2002
Issue release date: February 2002

Number of Print Pages: 23
Number of Figures: 9
Number of Tables: 2

ISSN: 0254-9670 (Print)
eISSN: 1421-9948 (Online)

For additional information: http://www.karger.com/ECI


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.